Compound name
A-446
Target name
GLS
Affinity biochemical (nM)
31
Affinity on-target cellular (nM)
10.5
CG-Set
Other targets set
Recommended Concentration
100 nM
Compound EUbOPEN ID
EUB0001120a
SMILES
C(C(Nc1nnc(N2C[C@H]3C[C@@H]2CN3c2cccnn2)s1)=O)c1ccccc1
InChIKey
DLNFTRSEHUWEGO-HUUCEWRRSA-N
NCBI gene ID
2744
UniProt ID
O94925
Synonyms
GLS, GLS1, KIAA0838
Mode of action
Inhibitor
Negative control
A-426
Affinity biochemical definition
IC50
Affinity biochemical assay type
GLS Enzyme activity assay
Affinity Biochemical Source Knowledge
https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-446
Affinity biochemical relation
0
Affinity on-target cellular definition
IC50
Affinity on-target cellular assay type
CTG assay in A549 cells
Affinity on-target cellular source knowledge
https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-446
Affinity on-target cellular relation
0
Selectivity platform
GPCR panel (PDSD screen)
Selectivity platform number of targets
45
Selectivity remarks
Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potency of closest targets: Ki(HTR7) >10 µM, Ki(GABA/PBR) >10 µM, Ki(HTR1D) = 6453.57 nM; Selectivity within target family (GLS2 enzyme activity assay): IC50 >30 µM (> 1000 fold); Selectivity outside target family (probe selectivity observed in Proteome Integral Stability Assay): closest targets in CEREP binding assay at 10 μM (percent inhibition of control specific binding): ADORA3 (agonist radioligand) = 76.6%, CHRM1 (antagonist radioligand) = 92.6%, CHRM2 (antagonist radioligand) = 71.5%
Selectivity Source Knowledge
https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-446
Selectivity Number of Off-targets
0